[go: up one dir, main page]

ES2135703T3 - Composicion y procedimiento destinados para prevenir y tratar las inflamaciones con la ayuda de inmunoglobulina. - Google Patents

Composicion y procedimiento destinados para prevenir y tratar las inflamaciones con la ayuda de inmunoglobulina.

Info

Publication number
ES2135703T3
ES2135703T3 ES95909729T ES95909729T ES2135703T3 ES 2135703 T3 ES2135703 T3 ES 2135703T3 ES 95909729 T ES95909729 T ES 95909729T ES 95909729 T ES95909729 T ES 95909729T ES 2135703 T3 ES2135703 T3 ES 2135703T3
Authority
ES
Spain
Prior art keywords
immunoglobulin
prevent
help
composition
treat inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95909729T
Other languages
English (en)
Inventor
Martha Prof Eibl
Herrmann Dr Wolf
Josef W Mannhalter
Heinz Dr Leibl
Yendra Dr Linnau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22731867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2135703(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno AG filed Critical Immuno AG
Application granted granted Critical
Publication of ES2135703T3 publication Critical patent/ES2135703T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INFLAMACION PUEDE TRATARSE O PREVENIRSE COMPLETAMENTE A TRAVES DE LA ADMINISTRACION DE UNA PREPARACION QUE CONTENGA IGA. ESTAS PREPARACIONES TAMBIEN PUEDEN AFECTAR A LA INMUNOMODULACION. PREFERIBLEMENTE, LA PREPARACION INCLUYE IGA MULTIMERICA Y ESTA PRACTICAMENTE LIBRE DE IGG EN SUS DISTINTAS FORMAS. TAMBIEN PUEDEN ADMINISTRARSE OTROS COMPUESTOS, COMO ANTIBIOTICOS, AGENTES ANTIFLOGISTICOS Y ANTIACIDOS. LA INMUNOGLOBULINA A TAMBIEN PUEDE UTILIZARSE EN VACUNAS PARA PREVENIR LA INFLAMACION. TAMBIEN SE DESCRIBE UN ENSAYO MEJORADO PARA EVALUAR LA ACTIVIDAD ANTIINFLAMATORIA.
ES95909729T 1994-02-18 1995-02-16 Composicion y procedimiento destinados para prevenir y tratar las inflamaciones con la ayuda de inmunoglobulina. Expired - Lifetime ES2135703T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19806794A 1994-02-18 1994-02-18

Publications (1)

Publication Number Publication Date
ES2135703T3 true ES2135703T3 (es) 1999-11-01

Family

ID=22731867

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95909729T Expired - Lifetime ES2135703T3 (es) 1994-02-18 1995-02-16 Composicion y procedimiento destinados para prevenir y tratar las inflamaciones con la ayuda de inmunoglobulina.

Country Status (12)

Country Link
US (1) US5833984A (es)
EP (1) EP0744957B1 (es)
JP (1) JPH09509164A (es)
AT (2) ATE182793T1 (es)
AU (1) AU1809495A (es)
CA (1) CA2183566A1 (es)
DE (2) DE69511245T2 (es)
DK (1) DK0744957T3 (es)
ES (1) ES2135703T3 (es)
GR (1) GR3031691T3 (es)
IT (1) IT1281188B1 (es)
WO (1) WO1995022350A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
DE19600939C1 (de) * 1996-01-12 1997-08-28 Immuno Ag Verfahren zur Trennung von IgG und IgA
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
EP0839915A1 (en) * 1996-11-01 1998-05-06 Institut Suisse De Recherches Experimentales Sur Le Cancer Isrec Secretory immunoglobulin A as a mucosal vaccine delivery system
US20020114802A1 (en) * 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
JP2002542205A (ja) * 1999-04-19 2002-12-10 リチャード ワイスバート、 貯蔵ヒト免疫グロブリンおよび制酸剤の経口投与による成人リウマチ様関節炎の処置
CA2423805A1 (en) * 2000-09-28 2002-04-04 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin g
US20020098182A1 (en) * 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
WO2002028430A2 (en) * 2000-10-06 2002-04-11 Richard Weisbart Treatment of juvenile rheumatioid arthritis by oral administration of pooled human immunoglobulin and an antacid
US20040180045A1 (en) * 2001-09-28 2004-09-16 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
US20060057223A1 (en) * 2004-09-10 2006-03-16 Dimauro Thomas M Intradiscal production of autologous interleukin antagonist
WO2009065093A2 (en) * 2007-11-17 2009-05-22 University Of Medicine And Dentistry Of New Jersey Use of stem cells for wound healing
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US10716850B2 (en) 2014-12-31 2020-07-21 Wellin, Inc. Anti-inflammatory factor retentate, method of isolation, and use
CN114894911B (zh) * 2022-03-18 2023-10-24 辽宁成大生物股份有限公司 一种控制牛血清产品质量方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5837285B2 (ja) * 1975-05-29 1983-08-15 カブシキガイシヤ ミドリジユウジ チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ
JPS5653622A (en) * 1979-10-09 1981-05-13 Mochida Pharmaceut Co Ltd Preventive and remedy for infectious disease of respiratory organ and oral cavity
JPS5759815A (en) * 1980-09-30 1982-04-10 Mochida Pharmaceut Co Ltd Drug composition having preventing and remedying action on rotavirus infectious disease
DE3927111C3 (de) * 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
JP3145696B2 (ja) * 1990-10-05 2001-03-12 日本ケミカルリサーチ株式会社 分泌型免疫グロブリンａ製剤の製造法
AT402789B (de) * 1991-03-25 1997-08-25 Immuno Ag Pharmazeutische präparation auf basis von plasmaproteinen

Also Published As

Publication number Publication date
DK0744957T3 (da) 2000-03-06
US5833984A (en) 1998-11-10
DE19505287A1 (de) 1995-08-24
EP0744957B1 (en) 1999-08-04
CA2183566A1 (en) 1995-08-24
AT402790B (de) 1997-08-25
WO1995022350A1 (en) 1995-08-24
IT1281188B1 (it) 1998-02-17
ITTO950112A1 (it) 1996-08-17
ATA29495A (de) 1997-01-15
DE69511245D1 (de) 1999-09-09
DE69511245T2 (de) 1999-12-16
ITTO950112A0 (it) 1995-02-17
ATE182793T1 (de) 1999-08-15
AU1809495A (en) 1995-09-04
EP0744957A1 (en) 1996-12-04
JPH09509164A (ja) 1997-09-16
GR3031691T3 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
ES2135703T3 (es) Composicion y procedimiento destinados para prevenir y tratar las inflamaciones con la ayuda de inmunoglobulina.
ES2123323T3 (es) Asociacion de un compuesto con actividad antimicrobiana (por ejemplo lipoaminoacido n,n-octanoilglicina) y de un monoalquileter de glicerol y su uso como agente antimicrobiano.
NO981392D0 (no) Substituerte pyrazolylbenzensulfonamider for anvendelse i veterinærterapi som antiinflammatorisk middel
ES2170250T3 (es) Articulo absorbente desechable que tiene una lamina superior con locion y que contiene un emoliente y un agente inmovilizante de poliester de poliol.
ES2144151T3 (es) Benzotiazepinas hipolipidemicas.
ES2231826T3 (es) Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
ES2160712T3 (es) Nueva preparacion farmaceutica para tratamiento del dolor.
ES2157958T3 (es) Uso de venlafaxina o de un compuesto de ariloxipropanamina para la preparacion de un medicamento para el tratamiento de la incontinencia urinaria.
FI971440A7 (fi) Sukupuolitauteja vastaan suunnatun formulaation käyttötapa ja tätä sis ältävä koostumus
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
DK1059934T3 (da) Matrixproteinpræparater til sårheling
ES2124822T3 (es) Preparaciones para la aplicacion externa de agentes antisepticos y/o agentes que fomentan la curacion de heridas.
ES2180774T3 (es) La utilizacion de triacetato de glicerilo para el tratamiento de onicomicosis.
DE58901906D1 (de) Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz.
GB2347625A (en) Agent for treating allergic or hypersensivity condition
ES2095578T3 (es) Composicion para el tratamiento de mastitis y metritis.
FI945412L (fi) Alkoholit kaliumkanavan avaajina ja virtsanpidätyskyvyttömyyden hoidossa
NO941097D0 (no) Hudregenererende kosmetisk preparat
ES2087279T3 (es) El uso de giberelinas para el tratamiento de la prostatitis y la psoriasis.
ES2121109T3 (es) Composicion de champu.
BR9911904A (pt) Processo cosmético para a redução ou prevenção do mau cheiro do corpo, e, uso de um agente ativo.
DE69739482D1 (de) Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
AR010432A1 (es) Composiciones farmaceuticas que contienen acido ricinoleico y su uso para la terapia antiinflamatoria y analgesica
ATE189395T1 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
MX9703288A (es) Oxazolil- y tiazolilimidazo-benzo- y tienodiacepinas y su uso como medicamentos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 744957

Country of ref document: ES